US equities |
MU $983.23 ▲+5.86% META $612.49 ▼-1.24% GOOGL $324.89 ▲+1.34% NVDA $215.38 ▼-1.17% MSFT $531.01 ▼-0.06% TSLA $404.22 ▼-0.80% SPCX $145.23 ▼-2.25% SNDK $1,404.77 ▲+7.66%
FinancialContent

Silo Pharma, Inc. - Common Stock (NQ:SILO)

1.340 +0.050 (+3.88%)
Delayed Quote Updated: 3:49 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Silo Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
AINewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) QwikAgents Expands AI Platform With NVIDIA Support, Hermes Runtime
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Silo Pharma’s QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Receives U.S. Patent Notice of Allowance for PTSD Therapeutic SPC-15
Via Investor Brand Network
Topics Intellectual Property
News headline image
Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio
From Silo Pharma, Inc.
Via GlobeNewswire
MissionIRNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Participate in IPAC-RS 2026 Nasal Innovation Forum
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Receives Canadian Patent Allowance for Lead Asset SPC-15
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Granted European Patent Covering Novel PTSD Therapy
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Subsidiary QwikAgents Joins AMD AI Developer Program
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents 
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing 
From Silo Pharma, Inc.
Via GlobeNewswire
NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances SPC-15 Intranasal PTSD Program With Device Robustness Study
Via Investor Brand Network
News headline image
Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Launches Ibogaine-Based TBI Therapeutics Initiative
Via Investor Brand Network
Topics Intellectual Property
News headline image
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
From Silo Pharma, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Highlights Federal Momentum Advancing Psychedelic Therapeutics Development
Via Investor Brand Network
News headline image
Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
AINewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands Into AI With Qwikagents Asset Acquisition
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics
From Silo Pharma, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances IP Portfolio With EPO Notice of Intent to Grant Patent
Via Investor Brand Network
Topics Intellectual Property
News headline image
Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy
From Silo Pharma, Inc.
Via GlobeNewswire
MissionIRNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Authorizes $1 Million Share Repurchase Program
Via Investor Brand Network
News headline image
Silo Pharma Announces Share Buyback Program
From Silo Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >